Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sutro Biopharma (STRO) Prepaid Assets (2017 - 2025)

Historic Prepaid Assets for Sutro Biopharma (STRO) over the last 9 years, with Q3 2025 value amounting to $10.6 million.

  • Sutro Biopharma's Prepaid Assets fell 251.15% to $10.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $10.6 million, marking a year-over-year decrease of 251.15%. This contributed to the annual value of $17.8 million for FY2024, which is 8077.39% up from last year.
  • According to the latest figures from Q3 2025, Sutro Biopharma's Prepaid Assets is $10.6 million, which was down 251.15% from $18.5 million recorded in Q2 2025.
  • In the past 5 years, Sutro Biopharma's Prepaid Assets registered a high of $24.9 million during Q1 2025, and its lowest value of $7.5 million during Q1 2021.
  • In the last 5 years, Sutro Biopharma's Prepaid Assets had a median value of $10.3 million in 2023 and averaged $11.8 million.
  • Its Prepaid Assets has fluctuated over the past 5 years, first skyrocketed by 23268.51% in 2021, then tumbled by 4312.84% in 2024.
  • Sutro Biopharma's Prepaid Assets (Quarter) stood at $8.1 million in 2021, then soared by 43.63% to $11.7 million in 2022, then decreased by 15.61% to $9.8 million in 2023, then skyrocketed by 80.77% to $17.8 million in 2024, then plummeted by 40.46% to $10.6 million in 2025.
  • Its Prepaid Assets stands at $10.6 million for Q3 2025, versus $18.5 million for Q2 2025 and $24.9 million for Q1 2025.